MD-224 stands poised as an innovative candidate for a novel anticancer agent, representing a distinct class of therapeutic compounds. Functioning as a click chemistry reagent, it harbors an alkyne group, enabling it to engage in copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules featuring Azide groups.
Usually ships within 24 hours.